Pošalji zapis e-poštom: A74 COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED TO INFLIXIMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS